Kezar Life Sciences (NASDAQ:KZR) Upgraded to “Sell” at Wall Street Zen

Kezar Life Sciences (NASDAQ:KZR) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research note on Wednesday, July 16th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Kezar Life Sciences has a consensus rating of “Hold” and an average price target of $9.00.

Kezar Life Sciences Stock Performance

Shares of KZR opened at $3.95 on Friday. The company has a quick ratio of 7.29, a current ratio of 7.29 and a debt-to-equity ratio of 0.03. Kezar Life Sciences has a 52-week low of $3.62 and a 52-week high of $9.18. The company has a 50-day simple moving average of $4.15 and a 200-day simple moving average of $4.48. The company has a market capitalization of $28.93 million, a PE ratio of -0.41 and a beta of 0.61.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Wednesday, August 13th. The company reported ($1.87) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.28. Equities research analysts predict that Kezar Life Sciences will post -4.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. BML Capital Management LLC grew its stake in shares of Kezar Life Sciences by 55.6% in the second quarter. BML Capital Management LLC now owns 635,183 shares of the company’s stock valued at $2,909,000 after buying an additional 227,045 shares in the last quarter. Stonepine Capital Management LLC boosted its holdings in Kezar Life Sciences by 69.9% in the 2nd quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock worth $778,000 after acquiring an additional 69,859 shares during the period. Shay Capital LLC acquired a new stake in Kezar Life Sciences in the fourth quarter valued at approximately $398,000. Dimensional Fund Advisors LP purchased a new stake in shares of Kezar Life Sciences during the fourth quarter valued at approximately $217,000. Finally, Woodline Partners LP acquired a new position in shares of Kezar Life Sciences during the first quarter worth $125,000. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.